We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Advanced Pancreatic Cancer Who Have Progressed on Gemcitabine-Based Therapy.
- Authors
Lee, Min Geun; Lee, Sang Hyub; Lee, Seung June; Lee, Yoon Suk; Hwang, Jin-Hyeok; Ryu, Ji Kon; Kim, Yong-Tae; Kim, Dong Uk; Woo, Sang Myung
- Abstract
Background/Aims: There is no standard consensus on a strategy in the second-line setting for gemcitabine-refractory advanced pancreatic cancer. This study evaluated the activity and tolerability of oxaliplatin, irinotecan, 5-fluorouracil and leucovorin (FOLFIRINOX) as a second-line therapy in advanced pancreatic adenocarcinoma pretreated with a gemcitabine-based regimen. Methods: A retrospective survey was carried out on 18 patients with advanced pancreatic cancer who had been on gemcitabine-based chemotherapy and were then treated with FOLFIRINOX as a second-line therapy. Results: One patient (5.6%) had a confirmed complete response, 4 (22.2%) had confirmed partial responses and 5 (27.8%) had stable disease, resulting in a rate of disease control of 55.6% (95% CI, 33.3-77.8%). The median progression-free survival and median survival were 2.8 months and 8.4 months, respectively. Seven patients (38.9%) experienced grade 3-4 neutropenia. Grade 3 or 4 nonhematologic adverse events included nausea (38.9%) and vomiting (16.7%). Conclusions: These results suggest the modest clinical activity regarding efficacy and the acceptable toxicity profile with the FOLFIRINOX regimen as a second-line treatment. © 2014 S. Karger AG, Basel
- Subjects
FOLINIC acid; IRINOTECAN; OXALIPLATIN; CANCER chemotherapy; CANCER patients; PANCREATIC cancer; PANCREATIC cancer treatment; NEUTROPENIA; THERAPEUTICS
- Publication
Chemotherapy (0009-3157), 2014, Vol 59, Issue 4, p273
- ISSN
0009-3157
- Publication type
Article
- DOI
10.1159/000356158